芬兰婴儿10价肺炎球菌结合疫苗接种对成人侵袭性肺炎球菌疾病的长期人群影响
基于芬兰全国实验室监测的5610例≥18岁培养确诊侵袭性肺炎球菌疾病(IPD)病例,采用时间序列模型比较婴儿接种10价肺炎球菌结合疫苗(PCV10)前后血清型特异性IPD发病率及30天死亡率。PCV10血清型IPD发病率较预期下降90%,非PCV10血清型发病率较预期升高40%但随访末期趋于平稳,所有成人IPD观察值与预期值发病率比为0.7(95%CI 0.5-0.8)。
要点
- 婴儿PCV10接种后,成人PCV10血清型IPD发病率较无接种预期下降90%(12/10万人年)。
- 非PCV10血清型IPD发病率较预期升高40%(4.4/10万人年),但随访末期趋于平稳。
- 所有成人IPD观察值与预期值发病率比为0.7(95%CI 0.5-0.8),≥65岁人群为0.7(95%CI 0.5-0.95)。
核心结论
- 婴儿PCV10接种对所有成人年龄组的疫苗血清型IPD和总体IPD产生显著间接效应;非疫苗IPD发病率在PCV10项目实施5年后趋于稳定,形成非疫苗IPD占总体IPD近90%的稳态;老年人仍存在大量肺炎球菌疾病负担。
研究设计与样本
- 全国性人群随访研究,通过国家实验室监测识别≥18岁培养确诊IPD病例n=5610(85%为肺炎),链接人口登记数据,采用负二项回归时间序列模型比较PCV10前后血清型特异性IPD发病率及30天死亡率。
主要发现
- PCV10前时期(2004年7月-2010年6月),≥18岁成人总体IPD发病率每年增长4.8%。
- 调整趋势和季节性后,2018年7月-2019年6月观察到的PCV10血清型IPD发病率较无PCV10项目的预期率低90%(12/10万人年)。
- 非PCV10血清型IPD发病率较预期高40%(4.4/10万人年),血清型3、19A、22F和6C贡献了大部分率增加,但非PCV10 IPD发病率在随访末期趋于平稳。
- 所有IPD的观察值与预期值发病率比为0.7(95%CI 0.5-0.8),IPD相关30天死亡率的观察值与预期值发病率比为0.7(95%CI 0.3-1.3)。
- 病死比例从11.9%降至10.0%(p<0.01);≥65岁人群的观察值与预期值发病率比为0.7(95%CI 0.5-0.95)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data are available on long-term indirect effects of ten-valent pneumococcal conjugate vaccine (PCV10) programmes. We evaluated changes in invasive pneumococcal disease (IPD) incidence, mortality, and serotype distribution in adults up to 9 years after infant PCV10 introduction. METHODS: Culture-confirmed IPD cases ≥18 years (n = 5610; 85% were pneumonia) were identified through national, population-based laboratory surveillance; data were linked with population registry to conduct nationwide follow-up study. In a time-series model, we compared serotype-specific IPD incidence and associated 30-day mortality rates before and after PCV10 by using negative binomial regression models. RESULTS: During pre-PCV10 period (7/2004-6/2010), overall IPD incidence in adults ≥18 years increased yearly by 4.8%. After adjusting for trend and seasonality, the observed PCV10 serotype IPD incidence in 7/2018-6/2019 was 90% (12/100,000 person-years) lower than the expected rate without PCV10 program. Non-PCV10 serotype incidence was 40% (4.4/100,000 person-years) higher than expected; serotypes 3, 19A, 22F, and 6C accounted for most of the rate increase. However, incidence of non-PCV10 IPD levelled off by end of follow-up. The observed-expected incidence rate-ratio (IRR) was 0·7 (95 %CI 0·5-0.8) for all IPD and 0·7 (95 %CI 0·3-1·3) for IPD-associated 30-day mortality. Case-fatality proportion decreased from 11·9% to 10.0% (p < 0.01). In persons ≥65 years, the IRR was 0·7 (95 %CI 0·5-0.95). CONCLUSIONS: Significant indirect effects were seen for vaccine-serotype IPD and for overall IPD in all adult age groups. For non-vaccine IPD, the incidence stabilized 5 years after infant PVC10 program introduction, resulting in a steady state in which non-vaccine IPD accounted for nearly 90% of overall IPD. Substantial pneumococcal disease burden remains in older adults.
引用
- Nuorti JP, Rinta-Kokko H, Toropainen M, et al. Long-term population impact of infant 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Finland. Vaccine. 2022. PMID: 36075797. doi:10.1016/j.vaccine.2022.08.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。